Hausen A, Fuchs D, Grünewald K, Huber H, König K, Wachter H
Clin Chim Acta. 1981 Dec 24;117(3):297-305. doi: 10.1016/0009-8981(81)90117-0.
Urinary neopterine levels were studied in 79 normal subjects and in 112 patients with haematological neoplasias. The mean values in 79 patients with active disease were significantly raised compared to the control group. Results obtained in 79 patients with active disease indicate that 91% had neopterine levels higher than the mean value of 79 normal individuals +3 SD. There is only a little overlap between the range of neopterine levels in cancer patients and the range in healthy subjects. No significant difference was found between the mean urinary neopterine levels of 33 patients with non-Hodgkin's or with Hodgkin's lymphoma in remission and the healthy group. Only 15% of these patients had elevated neopterine levels. The mean urinary neopterine levels correlated well with the tumor stage in patients with chronic lymphocytic leukaemia and with non-Hodgkin's disease. In patients with chronic leukaemia those without hepatosplenomegaly excreted significantly more neopterine than controls, and patients with hepatosplenomegaly significantly more than those without hepatosplenomegaly. It is concluded that urinary neopterine levels are of value for following the progression of haematological neoplasias.
对79名正常受试者和112例血液系统肿瘤患者的尿新蝶呤水平进行了研究。与对照组相比，79例活动性疾病患者的平均值显著升高。在79例活动性疾病患者中获得的结果表明，91%的患者新蝶呤水平高于79名正常个体平均值+3标准差。癌症患者的新蝶呤水平范围与健康受试者的范围之间只有少量重叠。在33例非霍奇金淋巴瘤或霍奇金淋巴瘤缓解期患者与健康组之间，尿新蝶呤平均水平未发现显著差异。这些患者中只有15%的新蝶呤水平升高。慢性淋巴细胞白血病和非霍奇金病患者的尿新蝶呤平均水平与肿瘤分期密切相关。在慢性白血病患者中，无肝脾肿大者的新蝶呤排泄量显著高于对照组，有肝脾肿大者显著高于无肝脾肿大者。得出的结论是，尿新蝶呤水平对于监测血液系统肿瘤的进展有价值。
